Abstract 1218: Telomerase-specific GFP-expressing adenovirus enables fluorescence-guided surgery (FGS) for patient-derived orthotopic xenograft (PDOX) in nude mice

Abstract

Abstract We have previously developed the genetically-engineered GFP-expressing telomerase-specific oncolytic adenovirus (OBP-401) which selectively targets tumors. Our laboratory pioneered the patient-derived orthotopic xenografts (PDOX) model (Proc. Natl. Acad. Sci. USA 88, 9345-9349, 1991). In order to develop fluorescent-guided surgery (FGS) in the clinical setting, we used OBP-401 to label PDOX of pancreatic cancer in nude mice. OBP-401 (ip) effectively labeled pancreatic cancer PDOX in nude mouse models. GFP-expressing PDOX pancreatic tumors were readily resected using fluorescence-guided surgery (FGS). Our results suggest that OBP-401 therefore has clinical potential for labeling pancreatic cancer for FGS. This is particularly important in pancreatic cancer where positive margins result in most cases of standard surgery, leading to extremely low survival rates. Citation Format: Shuya Yano, Yukihiko Hiroshima, Ali Maawy, Matthew H.G. Katz, Jason B. Fleming, Hiroyuki Kishimoto, Atsushi Suetsugu, Fuminari Uehara, Shinji Miwa, Hiroshi Tazawa, Michael Bouvet, Toshiyoshi Fujiwara, Robert M. Hoffman. Telomerase-specific GFP-expressing adenovirus enables fluorescence-guided surgery (FGS) for patient-derived orthotopic xenograft (PDOX) in nude mice. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1218. doi:10.1158/1538-7445.AM2014-1218